U.S. markets closed
  • S&P Futures

    -2.50 (-0.06%)
  • Dow Futures

    -8.00 (-0.02%)
  • Nasdaq Futures

    +1.00 (+0.01%)
  • Russell 2000 Futures

    +1.80 (+0.08%)
  • Crude Oil

    +0.26 (+0.36%)
  • Gold

    -0.10 (-0.01%)
  • Silver

    -0.00 (-0.02%)

    +0.0013 (+0.11%)
  • 10-Yr Bond

    -0.0610 (-4.04%)
  • Vix

    +2.95 (+16.62%)

    +0.0015 (+0.11%)

    +0.0370 (+0.03%)

    -6.95 (-0.02%)
  • CMC Crypto 200

    -51.42 (-5.47%)
  • FTSE 100

    -135.96 (-1.90%)
  • Nikkei 225

    -54.22 (-0.19%)

Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Stock Research Monitor: OGEN, ONCE, and SBOT

LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on SESN sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com monitors Oragenics Inc. (NYSE American: OGEN), Spark Therapeutics Inc. (NASDAQ: ONCE), Stellar Biotechnologies Inc. (NASDAQ: SBOT), and Sesen Bio Inc. (NASDAQ: SESN). Companies in the Biotechnology industry harness cellular and biomolecular processes to develop technologies and products that help improve lives and the health of the planet. All you have to do is sign up today for this free limited time offer by clicking the link below.



Tampa, Florida headquartered Oragenics Inc.'s stock finished Thursday's session 0.58% lower at $0.56. A total volume of 727,486 shares was traded, which was above their three months average volume of 699,540 shares. The Company's shares are trading 56.02% below their 50-day moving average. Additionally, shares of Oragenics, which focuses on developing antibiotics against infectious diseases and treatments for oral mucositis, have a Relative Strength Index (RSI) of 26.06.

On July 17th, 2018, Oragenics announced the closing of an underwritten public offering of units for gross proceeds of approximately $13.8 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Get the full research report on OGEN for free by clicking below at:


Spark Therapeutics

On Thursday, shares in Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc. recorded a trading volume of 580,006 shares, which was above their three months average volume of 553,740 shares. The stock ended the session 2.34% lower at $75.54. The Company's shares have advanced 6.66% over the past year. The stock is trading 7.79% above its 200-day moving average. Moreover, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 35.51.

On July 19th, 2018, research firm RBC Capital Markets downgraded the Company's stock rating from 'Outperform' to 'Sector Perform'. Download our actionable research report on ONCE at:


Stellar Biotechnologies

Port Hueneme, California-based Stellar Biotechnologies Inc.'s shares closed the day 1.20% lower at $1.65. The stock recorded a trading volume of 56,696 shares. The Company's shares are trading 11.96% below their 50-day moving average. Additionally, shares of Stellar Biotechnologies, which engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin protein in Europe, North America, and Asia, have an RSI of 36.42.

On July 05th, 2018, Stellar Biotechnologies' Chairman of the Board, President, and CEO, Frank R. Oakes, issued a statement on the favorable Phase-2bstudy results published by Neovacs, S.A., a customer and joint venture partner. An excerpt of the statement reads: "In addition to achieving key endpoints, Neovacs reported potent and long-lasting biological activity of their therapeutic vaccine, which utilizes Stellar KLH as a carrier molecule. The KLH-conjugated vaccine also demonstrated a favorable safety profile among study participants.- Register for your free report coverage on SBOT at:


Sesen Bio

Shares in Cambridge, Massachusetts-based Sesen Bio Inc. finished 2.73% lower at $1.78. The stock recorded a trading volume of 325,675 shares. The Company's shares have advanced 13.02% over the past year. The stock is trading above its 200-day moving average by 25.51%. Furthermore, shares of Sesen Bio, which develops next-generation antibody-drug conjugate therapies for patients with cancer, have an RSI of 42.45. Get the free research report on SESN at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities